Valuation: Shanghai Rendu Biotechnology Co., Ltd.

Market Cap 1.89B 280M 242M 228M 207M 389M 26.82B 396M 2.67B 1.04B 13.43B 1.05B 1.03B 44.63B P/E 2024
-179x
P/E 2025 186x
Enterprise Value 1.08B 160M 138M 130M 118M 222M 15.27B 225M 1.52B 594M 7.65B 600M 587M 25.41B EV / Sales 2024
3.31x
EV / Sales 2025 6.55x
Free-Float
43.51%
Yield 2024
0.56%
Yield 2025 2.38%
05-14 Shanghai Rendu Biotechnology's share trade to resume from May 15 RE
05-14 Nanjing Haijing Pharmaceutical Co., Ltd. agreed to acquire 21.25% stake in Shanghai Rendu Biotechnology Co., Ltd. from Ju Jinliang, Qiming Weichuang Venture Capital Management Company Limited, Runcong Enterprise Management Center (Limited Partnership), China International Capital Corporation Limited, Qiming Ventures Fund III, Changzhou Jinxin Venture Capital Co., Ltd. and Novel Praise Limited for approximately CNY 520 million. CI
05-08 Rendu Biotech's Controlling Shareholder Eyes Share Transfer Deal MT
05-07 Trading in Shanghai Rendu Biotechnology's shares to halt RE
04-28 Shanghai Rendu Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
02-27 Shanghai Rendu Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
30/10/25 Shanghai Rendu Biotechnology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025 CI
29/08/25 Shanghai Rendu Biotechnology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025 CI
29/04/25 Shanghai Rendu Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
27/02/25 Shanghai Rendu Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024 CI
29/10/24 Shanghai Rendu Biotechnology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2024 CI
29/08/24 Shanghai Rendu Biotechnology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024 CI
20/08/24 Tranche Update on Shanghai Rendu Biotechnology Co., Ltd.'s Equity Buyback Plan announced on February 19, 2024. CI
1 day-1.31%
1 week-2.32%
Current month+9.77%
1 month+2.39%
3 months-11.33%
6 months-8.79%
Current year+0.85%
1 week 46.81
Extreme 46.81
50.5
1 month 40
Extreme 40
50.5
Current year 40
Extreme 40
63.56
1 year 40
Extreme 40
63.56
3 years 22.5
Extreme 22.5
63.56
5 years 22.5
Extreme 22.5
72
10 years 22.5
Extreme 22.5
72
Manager TitleAgeSince
Chief Executive Officer 43 09/12/2022
Chief Tech/Sci/R&D Officer 60 13/06/2007
Director of Finance/CFO 52 01/08/2015
Director TitleAgeSince
Chairman 60 13/06/2007
Director/Board Member 43 01/05/2008
Director/Board Member 61 21/10/2020
Change 5-day change 1-year change 3-year change Capi.($)
-1.31%-2.32%-4.82%+12.27% 280M
-1.46%-6.69%+167.00%+347.13% 21.1B
-0.75%-1.02%-42.96%-20.85% 9.96B
-3.54%+7.80%+319.84%+17.15% 7.31B
+0.01%0.00%+86.32%+51.28% 6.59B
-1.71%-4.13%-40.27% - 6.16B
+3.22%+6.11%-12.93%-8.79% 5.97B
+1.19%+0.81%+81.12%+106.81% 4.55B
-0.43%-2.96%-12.56%-16.95% 4.27B
+3.92%+3.82%-19.12%-32.61% 2.85B
Average -0.09%+0.64%+52.16%+50.60% 6.9B
Weighted average by Cap. -0.59%-1.03%+85.98%+124.86%

Financials

2024 2025
Net sales 177M 26.3M 22.71M 21.34M 19.41M 36.49M 2.51B 37.09M 250M 97.77M 1.26B 98.73M 96.58M 4.18B 162M 24.01M 20.74M 19.49M 17.72M 33.32M 2.3B 33.87M 228M 89.28M 1.15B 90.15M 88.19M 3.82B
Net income -7.81M -1.16M -1M -940K -855K -1.61M -111M -1.63M -11.01M -4.31M -55.46M -4.35M -4.25M -184M 10.09M 1.5M 1.29M 1.21M 1.1M 2.08M 143M 2.11M 14.22M 5.56M 71.62M 5.62M 5.49M 238M
Net Debt -798M -118M -102M -95.97M -87.28M -164M -11.31B -167M -1.12B -440M -5.66B -444M -434M -18.82B -815M -121M -104M -98.01M -89.14M -168M -11.55B -170M -1.15B -449M -5.78B -453M -444M -19.22B
Logo Shanghai Rendu Biotechnology Co., Ltd.
Shanghai Rendu Biotechnology Co Ltd is a China-based company mainly engaged in the research, development, production, and sales of molecular diagnostic reagents and equipment. The Company mainly operates three businesses. The reagent business is mainly engaged in the research, development, production, and sales of molecular diagnostic reagents for reproductive tract infections, respiratory tract infections, enteroviruses, and bloodborne infectious diseases, as well as other reagent products such as sample preservation solutions and nucleic acid extraction reagents. The instrument business is mainly engaged in the research, development, production, and sales of molecular diagnostic instruments such as the fully automated nucleic acid detection and analysis system (AutoSAT). The testing business is mainly engaged in the provision of clinical testing services, including pathogen detection for the genitourinary system, bloodborne pathogens, respiratory system, and digestive system.
Employees
239
Date Price Change Volume
14/08/26 CN¥48.78 -1.31% 379,562
13/08/26 CN¥49.43 +0.26% 375,954
12/08/26 CN¥49.30 +3.53% 617,115
11/08/26 CN¥47.62 -0.38% 497,122
10/08/26 CN¥47.80 -4.29% 1,066,875
  1. Stock Market
  2. Stocks
  3. 688193 Stock